Robert G. Maki - Concepedia

Author

Robert G. Maki

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

Bonnet, Françoise, Christina Messiou, H.W.B. Schreuder, Maki, R. G., Maki, Robert, R G Maki, R MAKI, R Maki, R. G. Maki, R. Maki

747

Publications

54.4K

Citations

109

H-Index

171

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Dana-Farber Cancer Institute Icahn School of Medicine at Mount Sinai The University of Texas MD Anderson Cancer Center Centre Léon Bérard

About

Robert G. Maki is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	60	134	19.9K
2	Health Sciences	21	33	3.3K
3	Natural Sciences	5	5	238
4	Engineering	3	3	299
5	Nursing	1	1	10

Robert G. Maki

251

Publications

43.8K

Citations

100

H-Index

Page 1

	Year	Citations
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge, New England Journal of Medicine	2010	4.5K
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial George D. Demetri, Peter Reichardt, Yoon‐Koo Kang, The Lancet Gastrointestinal OncologyMedicinePharmacologyPathologyPharmacotherapy	2012	1.4K
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial Hussein A. Tawbi, Melissa Burgess, Vanessa Bolejack, The Lancet Oncology OncologyPathologyAdvanced Soft-tissue SarcomaBone SarcomaImmune Checkpoint Inhibitor	2017	1.4K
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial Ronald P. DeMatteo, Karla V. Ballman, Cristina R. Antonescu, The Lancet Surgical OncologyGastrointestinal OncologyMedicineGastroenterologyAdjuvant Imatinib Mesylate	2009	1.3K
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors George D. Demetri, Margaret von Mehren, Cristina R. Antonescu, Journal of the National Comprehensive Cancer Network Surgical OncologyImmunologyGastroenterologyPathologySurgery	2010	1.2K
Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033 Charles D. Blanke, Cathryn Rankin, George D. Demetri, Journal of Clinical Oncology	2008	1.1K
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis Alice T. Shaw, Beow Y. Yeap, Benjamin Solomon, The Lancet Oncology Overall SurvivalAlk Gene RearrangementMedicineRetrospective AnalysisPathology	2011	880
Crizotinib in<i>ALK</i>-Rearranged Inflammatory Myofibroblastic Tumor James E. Butrynski, David R. D’Adamo, Jason L. Hornick, New England Journal of Medicine Lymphoid NeoplasiaTumoral PathologyMalignant DiseaseAlk-translocated ImtPathology	2010	851
Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation Cristina R. Antonescu, Peter Besmer, Tianhua Guo, Clinical Cancer Research	2005	826
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial George D. Demetri, Margaret von Mehren, Robin L. Jones, Journal of Clinical Oncology	2015	809

Page 1